| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 38.265 | 130.684 | 164.085 | 227.454 | 221.984 | 249.426 | 251.671 | 217.699 |
| Total Income - EUR | - | - | 38.265 | 130.760 | 164.236 | 227.457 | 222.000 | 249.840 | 256.847 | 217.750 |
| Total Expenses - EUR | - | - | 37.754 | 115.817 | 142.744 | 170.853 | 181.642 | 214.379 | 224.515 | 203.080 |
| Gross Profit/Loss - EUR | - | - | 512 | 14.943 | 21.492 | 56.603 | 40.358 | 35.461 | 32.332 | 14.670 |
| Net Profit/Loss - EUR | - | - | 129 | 13.627 | 19.850 | 54.735 | 38.138 | 33.388 | 30.453 | 9.993 |
| Employees | - | - | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 2 |
Check the financial reports for the company - Pharma Forever S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 0 | 1.157 | 4.159 | 4.150 | 3.286 | 34.412 | 25.602 | 19.468 |
| Current Assets | - | - | 10.058 | 24.867 | 32.829 | 63.803 | 63.820 | 73.937 | 58.961 | 46.114 |
| Inventories | - | - | 9.524 | 19.791 | 22.748 | 36.124 | 42.623 | 43.373 | 45.365 | 40.317 |
| Receivables | - | - | 0 | 372 | 451 | 367 | 375 | 26.389 | 1.974 | 810 |
| Cash | - | - | 534 | 4.704 | 9.630 | 27.312 | 20.822 | 4.175 | 11.622 | 4.987 |
| Shareholders Funds | - | - | 173 | 13.796 | 31.884 | 64.253 | 63.077 | 33.437 | 37.536 | 36.393 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 9.885 | 12.228 | 5.105 | 3.700 | 4.029 | 74.912 | 47.026 | 29.189 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Pharma Forever S.r.l.